Lantern Pharma is trading 6.48% down at $0.76 on October 12, 2026, with no clear company-specific catalyst identified. - The latest company announcements were Taiwan approvals for the next stage of its Phase 2 HARMONIC trial and an upcoming October 15 investor presentation; neither is reported to be driving the decline. - The broader market was nearly flat, providing no clear market-wide explanation. Available evidence points to an unexplained stock-specific move rather than a confirmed news catalyst.